A Patient With Parenteral Nutrition–Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide. (July 2016)

• Record Type: Journal Article
• Authors: Compher, Charlene; Levinson, Katherine Boothe; Cambor, Carolyn L.; Stoner, Nancy; Boullata, Joseph I.; Piarulli, Amanda; Kinosian, Bruce
• Is Part Of: JPEN, Journal of parenteral and enteral nutrition. Volume 40:Number 5(2016)
• Page Start: 725
• Page End: 729
• Publication Date: 2016-07
• Subjects: short bowel syndrome -- malabsorption -- growth factors -- glucagon-like peptide 2 -- teduglutide -- cardiovascular; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; 615.85484
• DOI: 10.1177/0148607114566466
• Languages: English
• ISSNs: 0148-6071

Abstract

Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted in approval of the drug by the Food and Drug Administration in 2012 as a treatment for parenteral nutrition–dependent short bowel syndrome in adults. This report presents the case study of a man with short bowel syndrome caused by portal vein thrombosis who had 4 years exposure to the drug at the time of his death due to cardiovascular disease.